REGN stock price continues to attract option traders, with open interest rising 18% in bullish contracts. This positioning suggests the market is bracing for a possible upside surprise from upcoming FDA review decisions. There are plenty of GARP (growth at a reasonable price) types of stocks in the healthcare scene right now. Whether you’re looking to play biotech, health insurance, or med-tech, there are great names that have the confidence of Wall Street analysts. Of the trio, analysts see the most upside potential (17.5%) in CI stock. To track analyst ratings and price targets for Regeneron Pharmaceuticals, check out Quiver Quantitative's $REGN forecast page. Strong quarterly results have kept REGN stock price elevated. At $937.03, the valuation reflects a forward P/E of 21.7, in line with sector averages but supported by above-average growth rates in product sales.